Ekso Bionics Holdings, INC 10-Q quarterly reports

Ekso Bionics reports Q1 2026 financial results, highlighting a net loss of $6.9 million and ongoing efforts to finalize a business combination with Applied Digital Cloud.

Ekso Bionics Holdings, Inc. reported a 2% revenue increase and a significant reduction in net loss for Q3 2025, while addressing going concern doubts and pursuing strategic transactions.

Ekso Bionics Holdings, Inc. reported a significant drop in second-quarter revenue and an increased operating loss, leading management to express substantial doubt about its ability to continue as a going concern without further financing.

Ekso Bionics' Q1 2025 revenue decreased by 10% year-over-year, driven by lower average selling prices in Enterprise Health and reduced EVO sales, while the company focuses on refining its CMS reimbursement process for Personal Health products.

Ekso Bionics' Q3 2024 results show a decrease in revenue compared to the same period last year, alongside reduced operating expenses and a net loss.

Ekso Bionics' second quarter 2024 results show a slight revenue decrease but improved gross margins and reduced operating expenses, alongside ongoing efforts to secure funding and navigate market challenges.

Ekso Bionics reported a net loss of $3.4 million for the first quarter of 2024, while also expressing substantial doubt about its ability to continue as a going concern.